Literature DB >> 32579835

Pembrolizumab for Early Triple-Negative Breast Cancer. Reply.

Peter Schmid1, Rebecca Dent2, Joyce O'Shaughnessy3.   

Abstract

Entities:  

Year:  2020        PMID： 32579835     DOI： 10.1056/NEJMc2006684

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  Screening of organoids derived from patients with breast cancer implicates the repressor NCOR2 in cytotoxic stress response and antitumor immunity.

Authors:  Kelvin K Tsai; Shenq-Shyang Huang; Jason J Northey; Wen-Ying Liao; Chung-Chi Hsu; Li-Hsin Cheng; Michael E Werner; Chih-Pin Chuu; Chandrima Chatterjee; Jonathon N Lakins; Valerie M Weaver
Journal:  Nat Cancer       Date:  2022-05-26

Review 2.  Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, Efficacy, and Challenges.

Authors:  Katarzyna Uchimiak; Anna M Badowska-Kozakiewicz; Aleksandra Sobiborowicz-Sadowska; Andrzej Deptała
Journal:  Clin Med Insights Oncol       Date:  2022-06-14

3.  Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer.

Authors:  Abirami Sivapiragasam; Prashanth Ashok Kumar; Ethan S Sokol; Lee A Albacker; Jonathan K Killian; Shakti H Ramkissoon; Richard S P Huang; Eric A Severson; Charlotte A Brown; Natalie Danziger; Kimberly McGregor; Jeffrey S Ross
Journal:  Cancer Med       Date:  2020-12-12       Impact factor: 4.452

4.  Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.

Authors:  Alberto Ocaña; Jose Ignacio Chacón; Lourdes Calvo; Antonio Antón; Mauro Mansutti; Joan Albanell; María Teresa Martínez; Ainhara Lahuerta; Giancarlo Bisagni; Begoña Bermejo; Vladimir Semiglazov; Marc Thill; Arlene Chan; Serafin Morales; Jesús Herranz; Ignacio Tusquets; Massimo Chiesa; Rosalía Caballero; Pinuccia Valagussa; Giampaolo Bianchini; Emilio Alba; Luca Gianni
Journal:  Front Oncol       Date:  2022-02-11       Impact factor: 6.244

Review 5.  Stromal Characteristics and Impact on New Therapies for Metastatic Triple-Negative Breast Cancer.

Authors:  Shelby A Fertal; Johanna E Poterala; Suzanne M Ponik; Kari B Wisinski
Journal:  Cancers (Basel)       Date:  2022-02-27       Impact factor: 6.639
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.